Fig. 4

Cryptolepine (CRYPT) effects on p-STAT3 (A) and IL-23 levels (B) in the presence of IL-6 in HepG2 cells. The cells were treated with cryptolepine in the presence of IL-6. The levels of total STAT3, p-STAT3 and IL-23 were assessed after 24 h. Cryptolepine and niclosamide additive effects on p-STAT3 (C) and IL-23 levels (D) in the presence of IL-6 in HepG2 cells. The cells were co-treated with cryptolepine (CRYPT) and niclosamide (NICLO) in the presence of IL-6. The levels of total STAT3, p-STAT3 and IL-23 were assessed after 24 hours. Data are presented as means and standard deviations of three independent experiments, with each experiment conducted in triplicate. *p < 0.05, **p < 0.01 and ***p < 0.001 corresponds to significant difference as determined by one-way ANOVA and Bonferroni’s test, ns: difference statistically not significant